• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

良性多发性硬化症:需要对这一实体有一个新的定义。

Benign multiple sclerosis: a new definition of this entity is needed.

机构信息

Department of Neurology, Institute for Neurological Research Raúl Carrea, FLENI, Buenos Aires, Argentina.

出版信息

Mult Scler. 2012 Feb;18(2):210-8. doi: 10.1177/1352458511419702. Epub 2011 Aug 24.

DOI:10.1177/1352458511419702
PMID:21865415
Abstract

BACKGROUND

To study a cohort of benign multiple sclerosis (BMS) patients beyond physical disability, including the evaluation of cognitive and social function, as well as fatigue, pain and MRI studies.

METHODS

A cohort of 342 patients was prospectively followed for 10.9 ± 0.71 years. Forty-three patients (12.5%) met the BMS diagnosis criteria [Expanded Disability Status Scale (EDSS) < 3 after at least 10 years' disease duration], undergoing full neurological examination every 6 months. Neuropsychological status, pain, fatigue, social functioning and work-related disability, as well as brain MRIs, were assessed yearly.

RESULTS

By the end of follow-up, 20 of 43 BMS patients (47%) had suffered cognitive impairment and 23 (53.3%) referred depression. Furthermore, 21 (48.8%) reported significant changes in pain intensity, with fatigue and environmental severity scores significantly increasing over time in 33-35% of patients. Finally, 32 BMS patients (74%) showed significant increase in the number of new or enlarging T2 lesions, gadolinium-enhanced lesions, and persistent black holes, without changes in EDSS. Thirty-five of 43 patients (81%) fulfilling the BMS diagnostic criteria showed significant worsening of cognitive function, fatigue, pain or depression during the 10-year follow-up.

CONCLUSIONS

Currently accepted criteria for BMS diagnosis may cause overestimation of true prevalence, underscoring the need for routine monitoring of non-motor symptoms and imaging studies, to help physicians improve diagnostic accuracy as well as therapeutic decision-making in this subgroup of MS patients.

摘要

背景

研究一组良性多发性硬化症(BMS)患者,超越身体残疾,包括认知和社会功能评估,以及疲劳、疼痛和 MRI 研究。

方法

前瞻性随访了 342 例患者,随访时间为 10.9±0.71 年。43 例(12.5%)符合 BMS 诊断标准[扩展残疾状况量表(EDSS)<3 年,至少 10 年病程],每 6 个月进行一次全面的神经系统检查。每年评估神经心理学状态、疼痛、疲劳、社会功能和与工作相关的残疾,以及脑 MRI。

结果

随访结束时,43 例 BMS 患者中有 20 例(47%)出现认知障碍,23 例(53.3%)出现抑郁。此外,21 例(48.8%)报告疼痛强度显著变化,疲劳和环境严重程度评分在 33-35%的患者中随时间显著增加。最后,32 例 BMS 患者(74%)显示新或扩大的 T2 病变、钆增强病变和持续黑洞的数量显著增加,而 EDSS 无变化。43 例符合 BMS 诊断标准的患者中有 35 例(81%)在 10 年随访期间认知功能、疲劳、疼痛或抑郁显著恶化。

结论

目前用于 BMS 诊断的标准可能导致对真实患病率的高估,强调需要常规监测非运动症状和影像学研究,以帮助医生提高这组 MS 患者的诊断准确性和治疗决策。

相似文献

1
Benign multiple sclerosis: a new definition of this entity is needed.良性多发性硬化症:需要对这一实体有一个新的定义。
Mult Scler. 2012 Feb;18(2):210-8. doi: 10.1177/1352458511419702. Epub 2011 Aug 24.
2
The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.长期“良性”多发性硬化症的心理社会和认知影响。
Mult Scler. 2011 Nov;17(11):1375-83. doi: 10.1177/1352458511410343. Epub 2011 Jun 15.
3
Patient reported outcomes in benign multiple sclerosis.良性多发性硬化症患者报告的结局。
Mult Scler. 2011 Jul;17(7):876-84. doi: 10.1177/1352458511398370. Epub 2011 Mar 3.
4
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.复发缓解型多发性硬化轻度残疾患者的认知障碍及其与疾病指标的关系:多发性硬化认知障碍(COGIMUS)研究的基线结果
Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.
5
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.神经心理学和磁共振成像测量可预测良性多发性硬化症的短期病情发展。
Neurology. 2009 Aug 18;73(7):498-503. doi: 10.1212/WNL.0b013e3181b351fd. Epub 2009 Jul 29.
6
A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.预期寿命正常的非进展性多发性硬化症患者的代表性队列。
Brain. 2012 Mar;135(Pt 3):900-11. doi: 10.1093/brain/awr336.
7
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study.良性多发性硬化症中相对皮质保留的证据:一项纵向磁共振成像研究。
Mult Scler. 2009 Jan;15(1):36-41. doi: 10.1177/1352458508096686. Epub 2008 Aug 28.
8
Cognitive impairment and structural brain damage in benign multiple sclerosis.良性多发性硬化症中的认知障碍与脑结构损伤
Neurology. 2008 Nov 4;71(19):1521-6. doi: 10.1212/01.wnl.0000319694.14251.95. Epub 2008 Sep 24.
9
In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.良性多发性硬化症患者大脑中存在稳定神经轴突损伤的体内证据。
Mult Scler. 2009 Jul;15(7):789-94. doi: 10.1177/1352458509103714. Epub 2009 May 22.
10
Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis.215 例多发性硬化症患者扩展残疾状况量表中认知障碍的整合。
Eur Neurol. 2010;64(6):345-50. doi: 10.1159/000322140. Epub 2010 Nov 13.

引用本文的文献

1
Early regional cerebral grey matter damage predicts long-term cognitive impairment phenotypes in multiple sclerosis: a 20-year study.早期脑区灰质损伤可预测多发性硬化症的长期认知障碍表型:一项20年的研究。
Brain Commun. 2024 Oct 12;6(6):fcae355. doi: 10.1093/braincomms/fcae355. eCollection 2024.
2
Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France.用克拉屈滨片对复发型多发性硬化症患者进行全面、长期管理:来自法国的专家意见。
Neurol Ther. 2024 Jun;13(3):503-518. doi: 10.1007/s40120-024-00589-7. Epub 2024 Mar 15.
3
Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis.
复发缓解型多发性硬化症恶性进展的预测因素及治疗挑战
Heliyon. 2024 Feb 17;10(4):e26658. doi: 10.1016/j.heliyon.2024.e26658. eCollection 2024 Feb 29.
4
Symptom Interconnectivity in Multiple Sclerosis: A Narrative Review of Potential Underlying Biological Disease Processes.多发性硬化症中的症状关联性:对潜在基础生物学疾病过程的叙述性综述
Neurol Ther. 2022 Sep;11(3):1043-1070. doi: 10.1007/s40120-022-00368-2. Epub 2022 Jun 9.
5
Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.多种多发性硬化症疾病修正疗法的使用模式与支出情况:一项回顾性队列研究,使用2010 - 2019年美国商业保险人群的理赔数据
Neurol Ther. 2022 Sep;11(3):1147-1165. doi: 10.1007/s40120-022-00358-4. Epub 2022 May 22.
6
Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.残疾改善与多发性硬化症中脑萎缩发展减少相关。
AJNR Am J Neuroradiol. 2020 Sep;41(9):1577-1583. doi: 10.3174/ajnr.A6684. Epub 2020 Aug 6.
7
Cytokine-chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement.视神经和脊髓为主型多发性硬化症患者的细胞因子-趋化因子和认知特征。
J Spinal Cord Med. 2021 May;44(3):411-417. doi: 10.1080/10790268.2019.1666238. Epub 2019 Sep 26.
8
Impairment and restrictions in possibly benign multiple sclerosis.可能良性多发性硬化症中的障碍和限制。
Brain Behav. 2019 Apr;9(4):e01259. doi: 10.1002/brb3.1259. Epub 2019 Mar 18.
9
Spatial distribution of white matter degenerative lesions and cognitive dysfunction in relapsing-remitting multiple sclerosis patients.复发缓解型多发性硬化症患者白质退行性病变与认知功能障碍的空间分布
Neurol Neurochir Pol. 2019;53(1):18-25. doi: 10.5603/PJNNS.a2018.0001. Epub 2019 Feb 11.
10
Recommendations for cognitive screening and management in multiple sclerosis care.多发性硬化症护理中的认知筛查和管理建议。
Mult Scler. 2018 Nov;24(13):1665-1680. doi: 10.1177/1352458518803785. Epub 2018 Oct 10.